CEL-SCI Corporation announced it will present the new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN), at the American Head and Neck Cancer Societyâs (AHNS) 11th Annual International Conference on Head and Neck Cancer on July 8-12, 2023 in Montreal, Canada. CEL-SCIâs IT-MATTERS pivotal Phase 3 study reported a statistically significant 14.1% absolute 5-year overall survival (OS) benefit in the intent to treat (ITT) subjects who received Multikine followed by surgery and radiotherapy, as compared to control subjects who received only standard of care (SOC) (surgery plus radiotherapy). The Company is pursuing marketing approval for Multikine in the treatment of head and neck cancer in the U.S., Canada and the European Union.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.215 USD | +4.74% | -2.44% | -55.88% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.88% | 62.83M | |
+2.97% | 94.74B | |
-3.68% | 37.28B | |
-11.80% | 32.68B | |
+74.21% | 27.72B | |
-13.88% | 16.19B | |
-2.29% | 13.88B | |
-12.21% | 11.58B | |
+188.83% | 10.92B | |
-53.94% | 9.54B |
- Stock Market
- Equities
- CVM Stock
- News CEL-SCI Corporation
- CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed